Skip to main content

Advertisement

SpringerLink
Log in

The Use of Cytokeratin Stain to Distinguish Barrett’s Esophagus from Contiguous Tissues: A Systematic Review

  • Review Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Our objective was to systematically review the existing literature regarding the use of cytokeratin (CK) stain in differentiating Barrett’s esophagus (BE) from tissues of the gastric cardia, corpus, or antrum, with or without intestinal metaplasia (IM). Pubmed was searched for full publications in English (1983–2005) addressing the use of CK for differentiation of BE from contiguous tissues. Information was collected on the study sample, blinding, the methods used for CK staining, and for defining and applying the gold standard tests. Test characteristics were obtained or calculated. Sixteen studies (containing 46 comparisons) met the inclusion and exclusion criteria. Immunostaining for CK 7 and 20 was generally highly specific in distinguishing long-segment BE from antrum IM, fundus IM, or noncardiac gastric IM; 27 comparisons showed statistically significant differences. However, only 8 of 15 comparisons (6 of 12 studies) reported significant differences in CK staining patterns between BE and gastric cardia IM with a high sensitivity (89%–100%) and specificity (83%–100%) for long-segment BE and lower estimates for short-segment BE, while the other seven comparisons showed no significant differences and a very low sensitivity. Examination by a blinded pathologist was reported in five of six positive studies and in only one of six of the negative studies. In addition, variation in the patient populations, use of surgical resection versus endoscopic biopsies, and biopsy sampling technique in endoscopic studies may have accounted for these differences. Finally, two studies did not find significant differences in CK staining patterns between BE and normal cardiac mucosa. In conclusions, CK immunostaining has not performed well in differentiating BE, especially short-segment BE, from cardia IM. There seems to be a spectrum bias where the accuracy varies with different tested populations. CK immunostaining distinguished well between BE and IM in noncardiac segments of the stomach; however, these comparisons are not clinically relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15):1972–1981

    Article  PubMed  Google Scholar 

  2. Winters C Jr, Spurling TJ, Chobanian SJ, et al. (1987) Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92(1):118–124

    PubMed  Google Scholar 

  3. Sampliner RE (2002) Barrett’s esophagus, a complication of GERD. Curr Treat Options Gastroenterol 5(1):45–50

    PubMed  Google Scholar 

  4. El Serag HB (2002) The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31(2):421–440

    Google Scholar 

  5. Bonino JA, Sharma P (2005) Barrett’s esophagus. Curr Opin Gastroenterol 21(4):461–465

    PubMed  Google Scholar 

  6. Fitzgerald RC (2005) Complex diseases in gastroenterology and hepatology: GERD, Barrett’s, and esophageal adenocarcinoma. Clin Gastroenterol Hepatol 3(6):529–537

    Article  PubMed  CAS  Google Scholar 

  7. El-Serag HB, Sonnenberg A, Jamal MM, Kunkel D, Crooks L, Feddersen RM (1999) Characteristics of intestinal metaplasia in the gastric cardia. Am J Gastroenterol 94(3):622–627

    Article  PubMed  CAS  Google Scholar 

  8. Sharma P, Morales TG, Sampliner RE (1998) Short segment Barrett’s esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 93(7):1033–1036

    PubMed  CAS  Google Scholar 

  9. Goldblum JR (2002) The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 6(1):67–73

    Article  PubMed  Google Scholar 

  10. Moll R (1997) Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 9:63–69

    Google Scholar 

  11. Moll R, Franke WW, Schiller D (1982) The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24

    Article  PubMed  CAS  Google Scholar 

  12. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, Gramlich TL (1999) Cytokeratin subsets can reliably distinguish Barrett’s esophagus from intestinal metaplasia of the stomach. Hum Pathol 30(3):288–294

    Article  PubMed  CAS  Google Scholar 

  13. Sarbia M, Donner A, Franke C, Gabbert HE (2004) Distinction between intestinal metaplasia in the cardia and in Barrett’s esophagus: the role of histology and immunohistochemistry. Hum Pathol 35(3):371–376

    Article  PubMed  Google Scholar 

  14. Kurtkaya-Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A (2003) The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable? BMC Clin Pathol 3(1):5

    Article  PubMed  Google Scholar 

  15. Flucke U, Steinborn E, Dries V, Monig SP, Schneider PM, Thiele J, Holscher AH, Dienes HP, Baldus SE (2003) Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.Histopathology 43(2):127–134

    Article  PubMed  CAS  Google Scholar 

  16. DeMeester SR, Wickramasinghe KS, Lord RV, Friedman A, Balaji NS, Chandrasoma PT, Hagen JA, Peters JH, DeMeester TR (2002) Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol 97(10):2514–2523

    Article  PubMed  Google Scholar 

  17. Mohammed IA, Streutker CJ, Riddell RH (2002) Utilization of cytokeratins 7 and 20 does not differentiate between Barrett’s esophagus and gastric cardiac intestinal metaplasia. Mod Pathol 15(6):611–616

    Article  PubMed  CAS  Google Scholar 

  18. Jovanovic I, Tzardi M, Mouzas IA, Micev M, Pesko P, Milosavljevic T, Zois M, Sganzos M, Delides G, Kanavaros P (2002) Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol Histopathol 17(2):445–454

    Google Scholar 

  19. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Gramlich TL (2001) The utility of cytokeratin subsets in distinguishing Barrett’s–related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology 38(4):307–311

    Article  PubMed  CAS  Google Scholar 

  20. Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, Odze RD (2001) Phenotype of Barrett’s esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 25(1):87–94

    Article  CAS  Google Scholar 

  21. Couvelard A, Cauvin JM, Goldfain D, Rotenberg A, Robaszkiewicz M, Flejou JF, Groupe d’Etude l’Oesophage de Barrett (2001) Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 49(6):761–766

    Google Scholar 

  22. El-Zimaity HM, Graham DY (2001) Cytokeratin subsets for distinguishing Barrett’s esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol 96(5):1378–1382

    Article  PubMed  CAS  Google Scholar 

  23. Gulmann C, Shaqaqi OA, Grace A, Leader M, Patchett S, Butler D, Kay E (2004) Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett’s esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett’s esophagus. Appl Immunohistochem Mol Morphol 12(2):142–147

    PubMed  CAS  Google Scholar 

  24. Schilling D, Spiethoff A, Rosenbaum A, Hartmann D, Eickhoff A, Jakobs R, Weickert U, Rebe M, Bohrer MH, Riemann JF (2005) Does cytokeratin7/20 immunoreactivity help to distinguish Barrett’s esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients. Pathol Res Pract 200(11–12):801–805

    Article  PubMed  CAS  Google Scholar 

  25. Wallner B, Sylvan A, Janunger KG, Bozoky B, Stenling R (2001) Immunohistochemical markers for Barrett’s esophagus and associations to esophageal Z–line appearance. Scand J Gastroenterol 36(9):910–915

    Article  PubMed  CAS  Google Scholar 

  26. Yagi K, Nakamura A, Sekine A (2005) Cytokeratin immunoreactivity patterns in short-segment Barrett’s esophagus in Japanese patients. J Gastroenterol Hepatol 20(6):929–934

    Article  PubMed  Google Scholar 

  27. Yim HJ, Lee SW, Choung RS, Kim YS, Kim JY, Lee HS, Song CW, Choi JH, Bak YT, Ryu HS, Hyun JH, Kim DS, Kim CH (2005) Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett’s oesophagus in Korea? Eur J Gastroenterol Hepatol 17(6):611–616

    Article  PubMed  CAS  Google Scholar 

  28. Shearer C, Going J, Neilson L, Mackay C, Stuart RC (2005) Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro–oesophageal reflux disease. Histopathology 47(3):268–275

    Article  PubMed  CAS  Google Scholar 

  29. Ormsby AH, Vaezi MF, Richter JE, Goldblum JR, Rice TW, Falk GW, Gramlich TL (2000) Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s esophagus. Gastroenterology 119(3):683–690

    Google Scholar 

  30. Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS (1997) Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium. Gastroenterology 112(3):760–765

    Article  PubMed  CAS  Google Scholar 

  31. Piazuelo MB, Haque S, Delgado A, Du JX, Rodriguez F, Correa P (2004) Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 17(1):62–74

    Article  PubMed  Google Scholar 

  32. Jaeschke R, Guyatt G, Sackett DL (1994) Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence–Based Medicine Working Group. JAMA 271(5):389–391

    Article  PubMed  CAS  Google Scholar 

  33. Zwas F, Shields HM, Doos WG (1986) Scanning electron microscopy of Barrett’s epithelium and its correlation with light microscopy and mucin stains. Gastroenterology 90:1932–1941

    PubMed  CAS  Google Scholar 

  34. Glickman JN, Ormsby AH, Gramlich TL, Goldblum JR, Odze RD (2005) Interinstitutional variability and effect of tissue fixative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus. Hum Pathol 36(1):58–65

    Article  PubMed  CAS  Google Scholar 

  35. Kendall C, Stone N, Shepherd N, Geboes K, Warren B, Bennett R, Barr H (2003) Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett’s oesophagus. J Pathol 200(5):602–609

    Article  PubMed  Google Scholar 

  36. Krishnadath KK, Reid BJ, Wang KK (2001) Biomarkers in Barrett esophagus. Mayo Clin Proc 76(4):438–446

    Google Scholar 

  37. Sauter G, Simon R (2002) Predictive molecular pathology. N Engl J Med 347(25):1995–1996

    Article  PubMed  Google Scholar 

  38. Falk GW (2003) Cytology in Barrett’s esophagus. Gastrointest Endosc Clin N Am 13(2):335–348

    Google Scholar 

  39. Dalma-Weiszhausz DD, Chicurel ME, Gingeras TR (2002) Microarrays and genetic epidemiology: a multipurpose tool for a multifaceted field. Genet Epidemiol 23(1):4–20

    Article  PubMed  Google Scholar 

  40. Selaru FM, Zou T, Xu Y, et al. (2002) Global gene expression profiling in Barrett’s esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 21(3):475–478

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Dr. El-Serag is a VA HSR&D Awardee (RCD00-013-2). NIH R21 DK 067366-02.

Author information

Authors and Affiliations

  1. Sections of Gastroenterology and Health Services Research, Houston Veterans Affairs Medical Center, and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

    Zhannat Nurgalieva, Angus Lowrey & Hashem B. El-Serag

  2. 2002 Holcombe Boulevard (152), Houston, Texas, 77030, USA

    Hashem B. El-Serag

Authors
  1. Zhannat Nurgalieva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angus Lowrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hashem B. El-Serag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hashem B. El-Serag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nurgalieva, Z., Lowrey, A. & El-Serag, H.B. The Use of Cytokeratin Stain to Distinguish Barrett’s Esophagus from Contiguous Tissues: A Systematic Review. Dig Dis Sci 52, 1345–1354 (2007). https://doi.org/10.1007/s10620-006-9399-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9399-3

Keywords

Search

Navigation